Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
While these agents are not yet formally approved for IIH, their potential dual benefit of weight loss and ICP reduction could substantially enhance the current management of IIH
They are injectable medications prescribed to help people with obesity or type 2 diabetes
and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice
To view a copy of this licence, visit About this article Cite this article De Lepeleire, J., Mishra, R.C., Verstraete, J
US$ 29.11
US$ 28.64
US$ 21.80
US$ 23.11
US$ 25.68
US$ 22.69
US$ 26.91
US$ 23.65
US$ 22.03
US$ 23.39
